News
The day at a glance · 3 min read
Mood · Cautious
+15
Sentiment, −100 to +100
JNJ Quarterly Dividend
$1.34+3.1%
Earnings Season Spotlight
MRK Stock Price
$120.15-1.05%
Drug Pricing Under Fire
GILD Price Target (Morgan Stanley)
$175from $171
Drug Pricing Under Fire
Key driverEarnings season momentum collides with intensifying drug pricing pressures as J&J reports and Merck, Gilead face patent and pricing controversies
Daily briefHealthcare· Money365.Market AI ·

J&J Earnings, Drug Pricing Battles Drive Healthcare Action

Johnson & Johnson reports Q1 results while Merck, Gilead face pricing scrutiny; AbbVie expands ovarian cancer data

Earnings Season Spotlight

Neutral
JNJ
Johnson & Johnson ($JNJ) delivered first-quarter 2026 results before the market open, demonstrating what the company characterized as a strong start to the year with accelerated growth. The healthcare giant's board raised the quarterly dividend by 3.1%, to $1.34 from $1.30, marking 64 consecutive years of dividend increases and extending its royal dividend status.
$JNJ remains focused on pharmaceuticals and medical devices following its 2023 consumer health division spinoff, with oncology powering current growth despite ongoing talc litigation challenges. The earnings report comes amid a busy week that includes Netflix results and bank earnings dominated by concerns about geopolitical conflict and private-credit market stability.

Drug Pricing Under Fire

Bearish
MRKGILD
Merck ($MRK) faces mounting criticism over its patent strategy for a blockbuster cancer drug, with reports highlighting how the company built a wall of patents to keep the drug's price and profits elevated. The stock closed at $120.15, down 1.05% in the most recent trading session. Meanwhile, Gilead Sciences ($GILD) drew protests over what critics termed extortionate AIDS drug pricing, adding to the sector's pricing pressures. Morgan Stanley analyst actions reflected continued confidence in $GILD, raising the price target to $175 from $171 with an Overweight rating as the firm updated biopharma coverage models reflecting IQVIA trends. Hospital markups often compound the cost burden for American patients beyond manufacturer pricing.

Pipeline Developments & Oncology Advances

Bullish

ABBV Stock Price

$206.47+19.1% (1Y)

ABBV 3-Year Return

41.5%

ABBV 5-Year Return

127.4%
ABBVMRKLLY
AbbVie ($ABBV) reported late-breaking Phase 2 data for mirvetuximab soravtansine-gynx (Elahere) in platinum-sensitive ovarian cancer, highlighting efficacy and safety in an underserved patient population. The company's shares stand at $206.47 with a one-year return of 19.1%, and longer-term performance showing 41.5% over three years and 127.4% over five years.
$ABBV also signed an exclusive licensing deal with Haisco covering a pain therapy, expanding its late-stage pain pipeline outside China. The FDA accepted a Priority Review for Daiichi Sankyo and Merck's ($MRK) biologics license application for ifinatamab deruxtecan in extensive stage small cell lung cancer, which could become the first B7-H3 directed antibody drug conjugate available for cancer treatment if approved.
Eli Lilly ($LLY) advanced a leukemia drug in late-stage trials with positive results, strengthening its pipeline beyond blockbuster weight-loss treatments.

GLP-1 Competition & Tech Partnerships

Bullish
LLY
Novo Nordisk, the maker of Wegovy, announced a partnership with OpenAI to accelerate drug development as the Danish drugmaker works to close the gap with Eli Lilly ($LLY) in the immensely lucrative weight-loss drug market. The collaboration represents a strategic effort to leverage artificial intelligence in pharmaceutical research and development.
$LLY continues to ride strong GLP-1 demand and pipeline momentum according to analyst coverage, maintaining competitive pressure in the obesity treatment space.

Managed Care & Analyst Activity

Neutral

UNH Stock Price

$313+2.85%

AMGN Price Target (Morgan Stanley)

$326+from $309

BMY Price Target (BofA)

$67from $68
UNHAMGNBMY
UnitedHealth Group ($UNH) closed at $313, gaining 2.85% from the previous trading session and outperforming the broader market. BofA analyst Kevin Fischbeck raised the price target on $UNH while maintaining a Neutral rating as the health insurer navigates its dual business model spanning UnitedHealthcare insurance and Optum health services. Morgan Stanley updated coverage across multiple biopharma names, raising Amgen's ($AMGN) price target to $326 from $309 with an Equal Weight rating ahead of Q1 results, reflecting updated IQVIA trends and intra-quarter developments.
Bristol-Myers Squibb ($BMY) saw BofA lower its price recommendation to $67 from $68 while reiterating a Buy rating, making adjustments alongside a Q1 preview.

Looking Ahead

Neutral
JNJMRKGILDLLY
The healthcare sector faces a pivotal period as earnings season intensifies with major pharmaceutical and managed care companies reporting quarterly results. Regulatory scrutiny around drug pricing strategies appears to be escalating, particularly for legacy blockbuster products protected by patent portfolios. Clinical data readouts continue to drive individual stock performance, with oncology and specialty therapeutics maintaining investor attention alongside the ongoing GLP-1 market competition that has reshaped pharmaceutical industry dynamics.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy